The Best AI Stock to Own in the World Today is Trading for Just $25

“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.

Jerrold Dotson Biography and Net Worth

CFO of Vistagen Therapeutics

Jerrold D. Dotson, CPA has served as our Chief Financial Officer since September 2011, as our Corporate Secretary since October 2013 and as a Vice President since February 2014. Mr. Dotson previously served as Corporate Controller for Discovery Foods. Mr. Dotson also held various positions in the finance and administration department of Calypte Biomedical Corporation, including his last position as Vice President of Finance and Administration. Prior to joining Calypte, Mr. Dotson worked in various financial management positions, including Chief Financial Officer, for California & Hawaiian Sugar Company, a privately held company. Mr. Dotson is licensed as a CPA in California and received his B.S. degree (Cum Laude) in Business Administration with a concentration in accounting from Abilene Christian College.

What is Jerrold Duane Dotson's net worth?: The estimated net worth of Jerrold Duane Dotson is at least $11,402.20 as of September 7th, 2021. Mr. Dotson owns 2,426 shares of Vistagen Therapeutics stock worth more than $11,402 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Dotson may own. Learn More about Jerrold Duane Dotson's net worth.
How do I contact Jerrold Duane Dotson?: The corporate mailing address for Mr. Dotson and other Vistagen Therapeutics executives is 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA, 94080. Vistagen Therapeutics can also be reached via phone at (650) 577-3600 and via email at [email protected]. Learn More on Jerrold Duane Dotson's contact information.
Has Jerrold Duane Dotson been buying or selling shares of Vistagen Therapeutics?: Jerrold Duane Dotson has not been actively trading shares of Vistagen Therapeutics during the past quarter. Most recently, Jerrold Duane Dotson sold 1,000 shares of the business's stock in a transaction on Tuesday, September 7th. The shares were sold at an average price of $93.60, for a transaction totalling $93,600.00. Following the completion of the sale, the chief financial officer now directly owns 2,426 shares of the company's stock, valued at $227,073.60. Learn More on Jerrold Duane Dotson's trading history.
Who are Vistagen Therapeutics' active insiders?: Vistagen Therapeutics' insider roster includes Jerrold Dotson (CFO), and H. Snodgrass (Insider). Learn More on Vistagen Therapeutics' active insiders.
Are insiders buying or selling shares of Vistagen Therapeutics?: During the last twelve months, Vistagen Therapeutics insiders bought shares 1 times. They purchased a total of 775,756 shares worth more than $17,958,751.40. The most recent insider tranaction occured on August, 7th when Major Shareholder Commodore Capital Lp bought 775,756 shares worth more than $17,958,751.40. Insiders at Vistagen Therapeutics own 1.0% of the company. Learn More about insider trades at Vistagen Therapeutics.
Information on this page was last updated on 8/7/2023.

Jerrold Duane Dotson Insider Trading History at Vistagen Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/7/2021	Sell	1,000	$93.60	$93,600.00	2,426

Jerrold Duane Dotson Buying and Selling Activity at Vistagen Therapeutics

Vistagen Therapeutics Company Overview

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $4.70

$4.55

$4.77

50 Day Range

MA: $4.77

$3.92

$5.42

2 Week Range

Now: $4.70

$1.62

$24.71

Volume

193,744 shs

Average Volume

278,775 shs

Market Capitalization

$126.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.77

The Best AI Stock to Own in the World Today is Trading for Just $25

From Banyan Hill Publishing | Ad

See how you can invest alongside him